IL6 and Hepatic fibrosis: An HFD with 10 and 15% of JPS improved glucose sensitivity (reduction of 43 and 47%, respectively) and insulin, IL-6 (interleukin-6), and TNF-α plasma levels, besides decreasing aspartate aminotransferase (AST) and ALT levels (by up to 21 and 35 U/L, respectively), liver lipid accumulation (around 60% of reduction), liver fibrosis, tissue inflammation, and expression of hepatic lipid metabolism genes (HMGCoA, SREBP-1, and AMPK).